Xin Huang

30PUBLICATIONS
159CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyHaematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Apr 09, 2025
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins.

Jia-Nan Gong, Tirta M Djajawi, Donia M Moujalled

|Mar 05, 2025
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.

Kaiming Li, Yu Q Yap, Donia M Moujalled

|Oct 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.

Meng-Xiao Luo, Tania Tan, Marie Trussart

|Oct 07, 2024
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.

Fiona C Brown, Xin Wang, Richard Birkinshaw

|Oct 25, 2023
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.

Zilu Wang, Matteo Burigotto, Sabrina Ghetti

|Dec 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.

Charis E Teh, Hongke Peng, Meng-Xiao Luo

Pageof 5

Frequent Collaborators

13 joint publications

Andrew W Roberts

6 joint publications

Guillaume Lessene

5 joint publications

Fiona C Brown

5 joint publications

Thomas E Lew